Stockreport

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 [Yahoo! Finance]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF Topline data readout planned for the second quarter of 2025 SAN DIEGO, December 16, 2024 BUSINESS WIRE )--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or th [Read more]